ADA: Lilly's Trulicity bests Novo's Victoza, AZ's Bydureon in real-world study

Locked in a tight market share race with Novo Nordisk's Victoza, Trulicity is a key drug for Eli Lilly as patent expirations and competition take a toll. This weekend at the American Diabetes Association's annual meeting, the company presented data it hopes will give its med an edge over rivals in the GLP-1 class.